Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANC-501 in Major Depressive Disorder
NCT05439603Phase 2Completed
- Sponsor
- Ancora Biotech
- Start
- Sep 2022
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ANC-501 in major depressive disorder (MDD), sponsored by Ancora Biotech. Started Sep 2022; status: completed.
02
Drugs
ANC-501
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT05439603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05439603.